ANIK Q4 2021 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$213M

Q4 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$36M+9.6% YoY

Gross Profit

$18M50.6% margin

Operating Income

-$9M-25.5% margin

Net Income

-$6M-16.2% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

-9.4%

Cash Flow

Operating Cash Flow

$4M

Free Cash Flow

$3M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$348M

Total Liabilities

$60M

Stockholders' Equity

$287M

Cash & Equivalents

$94M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$33M	+9.6%
Gross Profit	$18M	$17M	+8.3%
Operating Income	-$9M	-$18M	+49.2%
Net Income	-$6M	-$16M	+63.0%

Revenue Segments

Product

$36M73%

Joint Preservation and Restoration

$13M27%

Geographic Segments

UNITED STATES

$28M85%

Europe

$5M15%